Novo Nordisk A/S (NVO) Stock Price, News & Analysis

Company Overview

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments. Novo Nordisk has been a major commercial and scientific driver of GLP-1 receptor agonists, marketed under well-known brand names for glucose control and weight management. In addition to diabetes and obesity medicines, the company supplies treatments for haemophilia and other rare bleeding disorders, as well as growth disorders and hormone replacement therapies. Its offerings combine pharmaceuticals with delivery devices and patient services aimed at improving adherence and outcomes.

Research and development are central to Novo Nordisk’s strategy, with continued investment in next-generation medicines for metabolic, cardiovascular and rare diseases. The company operates global manufacturing and distribution networks and markets its products broadly, with significant commercial operations in the United States, Europe and other international markets. Novo Nordisk also engages in partnerships and licensing arrangements with academic institutions, biotechnology firms and healthcare organizations to support innovation and expand access to therapies.

Leadership is focused on long-term innovation and patient-centric care; the company is led by President and CEO Lars Fruergaard Jørgensen. Novo Nordisk positions itself as a specialist pharmaceutical company with a mission to improve the lives of people with chronic conditions through medical innovation, comprehensive treatment solutions and support services for patients and healthcare providers.

Key Stats

• Today's Range: $45.15 to $45.89
• 50-Day Range: $35.28 to $47.13
• 52-Week Range: $35.12 to $81.44
• Volume: 6.38 million shs
• Average Volume: 20.82 million shs
• Market Capitalization: $203.93 billion
• P/E Ratio: 10.72
• Dividend Yield: 3.83%
• Price Target: $65.56
• Consensus Rating: Hold

Novo Nordisk A/S Stock Analysis - MarketRank™

Novo Nordisk A/S scored higher than 88% of companies evaluated by MarketBeat, and ranked 72nd out of 871 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Hold

Consensus Rating

Novo Nordisk A/S has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on no strong buy ratings, 4 buy ratings, 18 hold ratings, and 1 sell rating.

Upside Potential

Novo Nordisk A/S has a consensus price target of $65.56, representing about 44.1% upside from its current price of $45.51.

Amount of Analyst Coverage

Novo Nordisk A/S has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -0.58%

Earnings Growth

Earnings for Novo Nordisk A/S are expected to decrease by -0.58% in the coming year, from $3.46 to $3.44 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Novo Nordisk A/S is 10.68, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.18.

Price to Earnings Ratio vs. Sector

The P/E ratio of Novo Nordisk A/S is 10.68, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.39.

Price to Earnings Growth Ratio

Novo Nordisk A/S has a PEG Ratio of 3.97. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Novo Nordisk A/S has a P/B Ratio of 6.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.49% of the float of Novo Nordisk A/S has been sold short.

Short Interest Ratio / Days to Cover

Novo Nordisk A/S has a short interest ratio ("days to cover") of 1.21, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Novo Nordisk A/S has recently increased by 55.21%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 3.3 / 5
• Dividend Strength: Strong

Dividend Leadership

Novo Nordisk A/S is a leading dividend payer. It pays a dividend yield of 3.92%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Novo Nordisk A/S does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Novo Nordisk A/S is 41.08%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Novo Nordisk A/S will have a dividend payout ratio of 50.87% next year. This indicates that Novo Nordisk A/S will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.83

News Sentiment

Novo Nordisk A/S has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 45 news articles for Novo Nordisk A/S this week, compared to 11 articles on an average week.

Search Interest

152 people have searched for NVO on MarketBeat in the last 30 days. This is an increase of 9% compared to the previous 30 days.

MarketBeat Follows

45 people have added Novo Nordisk A/S to their MarketBeat watchlist in the last 30 days. This is an increase of 73% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Novo Nordisk A/S insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.07% of the stock of Novo Nordisk A/S is held by insiders.

Percentage Held by Institutions

11.54% of the stock of Novo Nordisk A/S is held by institutions.

Company Calendar

• Record date for 4/8 Dividend: 3/30/2026
• Ex-Dividend for 4/8 Dividend: 3/30/2026
• Last Earnings: 3/31/2026
• Dividend Payable: 4/08/2026
• Today: 5/29/2026
• Next Earnings (Estimated): 8/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Large Cap Pharma
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:NVO
• CIK: 353278
• Web: www.novonordisk.com
• Phone: (454) 444-8888
• Fax: 45-4449-0555
• Employees: 69,505
• Year Founded: 1923

Price Target and Rating

• Average Price Target for Novo Nordisk A/S: $65.56
• High Price Target: $175.00
• Low Price Target: $40.00
• Potential Upside/Downside: +43.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.13
• Research Coverage: 23 Analysts

Profitability

• EPS (Trailing Twelve Months): $4.26
• Trailing P/E Ratio: 10.72
• Forward P/E Ratio: 13.17
• P/E Growth: 3.97
• Net Income: $15.51 billion
• Net Margins: 37.23%
• Pretax Margin: 47.66%
• Return on Equity: 63.31%
• Return on Assets: 22.19%

Debt

• Debt-to-Equity Ratio: 0.59
• Current Ratio: 0.79
• Quick Ratio: 0.56

Sales & Book Value

• Annual Sales: $46.80 billion
• Price / Sales: 4.35
• Cash Flow: $4.80 per share
• Price / Cash Flow: 9.50
• Book Value: $7.12 per share
• Price / Book: 6.40

Miscellaneous

• Outstanding Shares: 4,465,000,000
• Free Float: 4,461,875,000
• Market Cap: $203.49 billion
• Optionable: Optionable
• Beta: 0.77